Pemazyre (Pemigatinib)
- Medicine Name: Pemazyre
- Generic Name: Pemigatinib
- Dosage Form & Strength: Tablets: 4.5mg, 9mg & 13.5mg
- Manufactured By: Incyte Corporation
Medical Uses
Pemazyre is a kinase inhibitor used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Recommended Dosage: The recommended dosage is 13.5 mg orally once a day for 2 consecutive weeks followed by 1 week off therapy, in 3 week cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Take pemazyre tablets with or without food at around the same time every day. Swallow tablets completely. Do not chew, crush, split, or dissolve tablets. In case the patient misses any dose by 4 or more hours or in case vomiting occurs, dosing should be resumed with the upcoming scheduled dose.
Warning & Precautions
- Tablets of pemazyre can cause RPED, which may cause signs/symptoms such as blurred vision, visual floaters, or photopsia. Comprehensive ophthalmological examination needs to be done including OCT before initiating pemazyre 9 mg / 4.5 mg / 13.5 mg tablet therapy and every 2 months for the initial 6 months and every 3 months thereafter while on treatment.
- Monitor patients for hyperphosphatemia and start a low phosphate diet when the level of serum phosphate is > 5.5 mg/dL. For the serum phosphate levels > 7 mg/dL, start phosphate lowering therapy and withhold, reduce the dose, or permanently interrupt pemazyre tablet 4.5mg / 9mg / 13.5mg based on time-span and severity of hyperphosphatemia.
- Findings in animal study and its mechanism of action suggest that pemazyre may cause fetal harm in cases administered to pregnant females. Advise females reproductive age to use effective contraception while on treatment with pemazyre tablet 13.5mg / 9mg / 4.5mg and for 1 week after the final dose.
Documentation & Availability
What documents are required to import PEMAZYRE to India?
PEMAZYRE (Pemigatinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation are needed to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is PEMAZYRE available in India?
PEMAZYRE (pemigatinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Chennai, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
PEMAZYRE can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of PEMAZYRE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com for Pemazyre price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the PEMAZYRE (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Pemazyre®?
Pemigatinib is Generic Name for the trade name drug Pemazyre®.
What is the Manufacturer Name of Pemazyre®?
Pemazyre® is manufactured by Incyte Corporation.
Is Pemazyre® approved by the FDA?
Yes, Pemazyre® is approved by the FDA. Date of approval: April 17, 2020.
What is Pemazyre®?
Pemazyre® is the first FDA-approved prescription agent that is aimed to treat adult patients with bile duct cancer (cholangiocarcinoma) that has spread or difficult to be removed by surgery:
- who have already treated with previous therapy, and
- whose tumor has a certain kind of abnormal “FGFR2” gene
What is the dosage and form of Pemazyre® supplied?
Pemazyre® is supplied as Tablets: 4.5mg, 9mg & 13.5mg for oral administration.
What are the most common side effects due to Pemazyre®?
Most common side effects due to Pemazyre® include: nail toxicity, hyperphosphatemia, alopecia, diarrhea, fatigue, dysgeusia, constipation, nausea, stomatitis, dry eye, dry mouth, vomiting, arthralgia, decreased appetite, back pain, abdominal pain, hypophosphatemia, and dry skin.
How much does Pemigatinib cost in India?
The pemigatinib cost in India is less and reasonable. In order to procure this cholangiocarcinoma medication authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Pemazyre®?
Store the tablets of Pemazyre at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
What are the Highlights of prescribing information for Pemazyre®?
Click Here to download full Pemazyyre prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
